



Local Coverage Determination (LCD): C-Reactive Protein High Sensitivity Testing (hsCRP) (L30256)

Contractor Information

Contractor Name Novitas Solutions, Inc.	Contract Number 12502	Contract Type A and B MAC
---	---------------------------------	--

LCD Information

Document Information

LCD ID L30256	Jurisdiction Pennsylvania
LCD Title C-Reactive Protein High Sensitivity Testing (hsCRP)	Original Effective Date For services performed on or after 10/28/2009
Revision Effective Date For services performed on or after 09/01/2014	Retirement Date N/A
Notice Period Start Date 05/17/2012	Notice Period End Date N/A
Revision Ending Date N/A	<p>AMA CPT / ADA CDT Copyright Statement CPT only copyright 2002 - 2015 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.</p> <p>The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2010 are trademarks of the American Dental Association.</p> <p>UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA." Health Forum reserves</p>

the right to change the copyright notice from time to time upon written notice to Company.

CMS National Coverage Policy

Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.

Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.

Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider for any claim that lacks the necessary information to process the claim.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

C-reactive protein,(CRP), is a nonspecific, acute-phase reactant produced in response to tissue injury, inflammation or infection. As an acute phase reactant, concentrations rise rapidly and half-life is short. Studies have shown that chronic, low-grade inflammation contributes to atherogenesis and the development of coronary artery disease (CAD). Inflammatory changes lead to progressive disease, which culminates in plaque instability, rupture, thrombosis, and myocardial infarction (MI).

CRP testing, CPT code *86140*, is eligible for coverage as a diagnostic test for the detection and evaluation of infection, tissue injury, and inflammatory disease. This CPT code, *86140*, is not to be used in place of CPT code *86141*, which represents high sensitivity C-reactive protein (hsCRP) testing and the subject of this policy.

A high sensitivity C-reactive protein (hsCRP) assay measures low levels of CRP, which allows for measurement of conditions indicative of chronic, low-grade inflammation. The stimulus for the rise in serum CRP in CAD remains undetermined, although it may result from local inflammation within atheromatous plaques, from a systemic or local inflammation or infection elsewhere in the body that contributes to atherogenesis, or to unrelated conditions. Increased CRP may reflect plaque instability and an increased risk for a CAD event. Published literature presents strong evidence to refute the hypothesis that CRP itself has a causative effect on coronary heart disease.

High-sensitivity assays can measure levels as low as 0.175 mg/L, which may be associated with CAD. HsCRP assays are based on nephelometric analysis of antigen-antibody complexes using monoclonal antibodies with sufficient sensitivity to detect low levels of CRP.

This contractor will consider high-sensitivity C-reactive protein (hsCRP) testing reasonable and necessary when ALL of the following criteria are met:

- When the hsCRP would add substantial incremental information in the decision making process to optimize/maximize lipid lowering pharmacologic therapy, (e.g., use of statins), in a patient who has been identified as being at intermediate risk for CAD (10-year risk of coronary heart disease between 10-20% per the ATPIII Guidelines). This is to be used for a one time decision point and is not intended to monitor therapy.
- The test is performed in patients considered to be metabolically stable and without obvious inflammatory or infectious conditions.

The American Heart Association (AHA) recommends the following cutpoints for hsCRP corresponding to three levels of risk:

- Low risk < 1.0 mg/L
- Average risk > 1.0 to < 3.0 mg/L
- High risk > 3.0 mg/L

Limitations

Medicare does not provide coverage for routine screening performed without a relationship to the evaluation or treatment of a symptom, sign, illness or injury. If high sensitivity C-reactive protein (hsCRP) testing is performed for cardiovascular risk assessment, in the absence of signs or symptoms of illness or injury, then the service will be denied as not reasonable and necessary.

Medicare does not cover hsCRP testing as a screening test for the general population or for monitoring response to therapy.

Although hsCRP is commonly elevated in inflammatory conditions (e.g., rheumatic fever, rheumatoid arthritis, systemic vasculitis, myocardial infarction, acute pancreatitis), measurements in these illnesses is not appropriate and is considered not reasonable and necessary.

Coding Information

Bill Type Codes

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

11x	Hospital Inpatient (Including Medicare Part A)
12x	Hospital Inpatient (Medicare Part B only)
13x	Hospital Outpatient
14x	Hospital - Laboratory Services Provided to Non-patients
22x	Skilled Nursing - Inpatient (Medicare Part B only)
23x	Skilled Nursing - Outpatient
72x	Clinic - Hospital Based or Independent Renal Dialysis Center
83x	Ambulatory Surgery Center
85x	Critical Access Hospital

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

0300	Laboratory - General Classification
0301	Laboratory - Chemistry
0302	Laboratory - Immunology
0303	Laboratory - Renal Patient (Home)
0304	Laboratory - Non-Routine Dialysis
0305	Laboratory - Hematology
0306	Laboratory - Bacteriology & Microbiology
0307	Laboratory - Urology
0309	Laboratory - Other Laboratory

CPT/HCPCS Codes

Group 1 Paragraph	
Italicized and/or quoted material is excerpted from the American Medical Association, <i>Current Procedural Terminology (CPT)</i> codes.	
Group 1 Codes	
86141	C-reactive protein hs

ICD-9 Codes that Support Medical Necessity

Group 1 Paragraph : For CPT/HCPCS code 86141:	
It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-9-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.	
Group 1 Codes	

272.0	PURE HYPERCHOLESTEROLEMIA
272.1	PURE HYPERGLYCERIDEMIA
272.2	MIXED HYPERLIPIDEMIA
272.3	HYPERCHYLOMICRONEMIA
272.4	OTHER AND UNSPECIFIED HYPERLIPIDEMIA
414.01	CORONARY ATHEROSCLEROSIS OF NATIVE CORONARY ARTERY
V49.89*	OTHER SPECIFIED CONDITIONS INFLUENCING HEALTH STATUS

*Use ICD-9-CM code V49.89 for patients at intermediate risk for CAD who do not have elevated lipids (i.e., do not meet criteria to use ICD-9-CM codes 272.0-272.4).

ICD-9 Codes that DO NOT Support Medical Necessity

General Information

Associated Information

Documentation Requirements

1. All documentation must be maintained in the patient's medical record and available to the contractor upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service(s)). The record must include the physician or non-physician practitioner responsible for and providing the care of the patient.
3. The submitted medical record must support the use of the selected ICD-9-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
4. The ordering physician should retain in the patient's medical record, history and physical examination notes documenting evaluation and management of one of the Medicare covered conditions/diagnoses, with relevant clinical signs/symptoms or abnormal laboratory test results, appropriate to one of the covered indications.
5. The patient's clinical record should further indicate changes/alterations in medications or management prescribed for the treatment of the patient.
6. There must be an attending/treating physician's order for each test documented in the patient's medical/clinical record.

Appendices

N/A

Utilization Guideline

In accordance with CMS Ruling 95-1 (V), utilization of these services should be consistent with locally acceptable standards of practice.

Generally, the measurement of hsCRP markers is performed twice (averaging results), optimally two weeks apart and fasting or nonfasting, with the average expressed in mg/L, in metabolically stable patients.

It is considered reasonable and necessary to perform no more than 3 hsCRP services per patient lifetime.

Sources of Information and Basis for Decision

Contractor is not responsible for the continued viability of websites listed.

Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes. *Diabetes* 2009; 58:926-933.

Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. *Circulation* 2005; 112:25-31.

Dehghan A, van Hoek M, Sijbrands EJJ, et al. Risk of type 2 diabetes mellitus attributable to C-reactive protein and other risk factors. *Diabetes Care* 2007; 7-10-2007.

Di Napoli M, Papa F; for the Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. *Stroke* 2002; 33:1763-

1771.

Elliott P, Chambers JC, Zhang W, et al. Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease. *JAMA* 2009; 302(1):37-48.

Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circ Cardiovasc Qual Outcomes* 2010; 122:e584-e636.

Grundy S M, Cleeman J I, Merz N B et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, *Circulation*. 2004; 110:227-239.

Hegele RA, Kraw ME, Ban MR, et al. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. *Arterioscler Thromb Vasc Biol* 2003; 23:111-116.

Kanapuru B, Ershler WB. Inflammation, Coagulation, and the Pathway to Frailty. *Am J Med* 2009; 122:605-613.

Kshirsagar A V, Bombeck A S, Bang H et al. Association of C-Reactive Protein and Microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). *Am J Cardiol* 2008; 101:401-406.

Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. *European Heart Journal* 2005; 26:2245-50.

Lloyd-Jones D M, Liu K, Tian L, et al. Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease. *Ann Intern Med*. 2006; 145:35-42.

McCulloch DK, Robertson RP. Risk Factors for Type 2 Diabetes Mellitus. In: UpToDate (electronic version). Hudson, Ohio, USA. Available at: <http://www.uptodateonline.com> (Accessed 04/30/2011).

McPherson & Pincus: Henry's Clinical Diagnosis and Management by Laboratory Methods, 21st ed. <http://www.mdconsult.com>. (Accessed 04/30/2009)

Melander O, Newton-Cheh C, Almgren P, et al. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. *JAMA* 2009; 302(1):49-57.

Morrow D A. C-Reactive Protein in Cardiovascular Disease In: UpToDate (electronic version). Hudson, Ohio, USA. Available at: <http://www.uptodateonline.com> (Accessed 04/30/2011).

Morrow DA, de Lemos JA, Sabatine MS. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the agrastat-to-zocor trial. *Circulation* 2006; 114:281-288.

O'Keefe JH, Carter MD, Lavie CJ. Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. *Mayo Clin Proc* 2009;84(8):741-757.

Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003; 107:499-511.

Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 2001; 286:327-334.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008; 359; 21:2195-2207.

Ridker PM, Danielson E, Rifai N, et al. Valsartan, Blood Pressure Reduction, and C-reactive protein. *Hypertension* 2006; 48:73-79.

Ridker PM, MacFadyen JG, Nordestgaard BG, et al. Rosuvastatin for Primary Prevention Among Individuals with Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk". *Circ Cardiovasc Qual Outcomes* 2010; 3:447-452.

Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *JAMA* 2005; 294:326-333.

Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002; 347:1557-1565.

Rogers A M, Shlipak M G. C-Reactive Proteins, Statins, and Cardiovascular Risk: What Can JUPITER Teach Us, Commentary on Ridker PM, Danielson E, Fonseca FA et al. *Am J of Kidney Dis* 2009; 53 (5) 737-740.

Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. *Circulation* 2002; 105:800-803.

Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study. *Stroke* 2001; 32:2575-2579.

Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular events among men with diabetes. *Diabetes Care* 2004; 27:889-894.

Shah SH, de Lemos JA. Editorial: Biomarkers and Cardiovascular Disease; Determining Causality and Quantifying Contribution to Risk Assessment. *JAMA* 2009; 302(1):92-93.

Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. *JAMA* 2003; 290:3000-3002.

Spatz ES, Canavan ME, Desai MM. From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999 2004 National Health and Nutrition Examination Survey. *Circ Cardiovasc Qual Outcomes* 2009;2:41-48.

Tanne D, Benderly M, Goldbourt U, et al. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. *Stroke* 2006; 37:1720-1724.

Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. *Circulation* 2002; 105:564-569.

Vainas T, Lubbers T, Stassen FRM, et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. *Circulation* 2003; 107:1103-1105.

Ventetuolo C E, Levy M M. Biomarkers: Diagnosis and Risk Assessment in Sepsis. *Clin Chest Med* 2008; 29:591-603.

Walston J, McBurnie MA, Newman A, et al. Frailty and Activation of the Inflammation and Coagulation Systems With and Without Clinical Comorbidities; Results From the Cardiovascular Health Study. *Arch Intern Med* 2002; 162:2333-2341.

Wilson P, Pencina M, Jacques P, et al. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study. *Circ Cardiovasc Qual Outcomes* 2008; 1:92-97.

Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. *Am Heart J* 2004; 147:931-938.

Zebrack JS, Muhlestein JB, Horne BD, et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. *J Am Coll Cardiol* 2002; 39:632-637.

Other Contractor(s)' Policies

Novitas Solutions Contractor Medical Directors

Revision History Information

Revision History

Revision Number	Effective Date	Explanation	Reason for Change
R3	09/01/2014	This revision updates the Novitas Solutions MAC numerical jurisdictional designation to the new MAC Lettered jurisdiction designation(s). No other changes were made to this LCD.	

Link to this LCD on the MCD:

Looking for more detail? View this policy at the CMS Medicare Coverage Database (MCD) for your state by choosing the appropriate link:

[Pennsylvania](#) | [Maryland](#) | [Delaware](#) | [District of Columbia](#) | [New Jersey](#)

Associated Documents

Attachments

N/A

Related Local Coverage Documents

N/A

Related National Coverage Documents

N/A

Keywords

N/A